rezetecan
Start here
An interim analysis of HERON-Lung01, a randomised, open-label phase 3 trial conducted in China, found that ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy in patients with EGFR-mutated advanced non-small-cell lung cancer whose disease had progressed after EGFR tyrosine kinase inhibitor therapy. The Lancet-published results also report a manageable safety profile and support the antibody-drug conjugate as a potential treatment option for this population. The analysis is interim, so overall survival and longer-term safety data are still awaited, as is the drug's regulatory positioning and broader use beyond the trial's Chinese cohort.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.comPick[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
Interim analysis of the Chinese randomised, open-label phase 3 trial HERON-Lung01 shows that ruzaltatug rezetecan significantly prolonged PFS over chemotherapy in EGFR-mutated advanced NSCLC that progressed after EGFR-TKI therapy. The original article reports a manageable safety profile and supports the drug as a potential treatment option for this population.
Heat trend for this story
Heat now 48·Peak in the comparable set 51 (Oct 26 17:00)·Change over 24h in the comparable set +1731%·Participants now 6
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.